Fluent Financial LLC Purchases New Shares in VanEck Pharmaceutical ETF $PPH

Fluent Financial LLC purchased a new position in VanEck Pharmaceutical ETF (NASDAQ:PPH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,992 shares of the company’s stock, valued at approximately $4,264,000. VanEck Pharmaceutical ETF accounts for about 1.5% of Fluent Financial LLC’s investment portfolio, making the stock its 18th largest position. Fluent Financial LLC owned 0.45% of VanEck Pharmaceutical ETF at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PPH. Wellington Management Group LLP purchased a new position in VanEck Pharmaceutical ETF during the fourth quarter valued at $42,134,000. Royal Bank of Canada grew its position in shares of VanEck Pharmaceutical ETF by 846.9% in the 1st quarter. Royal Bank of Canada now owns 361,001 shares of the company’s stock worth $37,501,000 after buying an additional 322,878 shares during the period. J.Safra Asset Management Corp increased its stake in shares of VanEck Pharmaceutical ETF by 6.9% in the 4th quarter. J.Safra Asset Management Corp now owns 305,472 shares of the company’s stock worth $31,516,000 after acquiring an additional 19,685 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of VanEck Pharmaceutical ETF by 176.2% in the 4th quarter. BNP Paribas Financial Markets now owns 300,000 shares of the company’s stock worth $30,951,000 after acquiring an additional 191,371 shares in the last quarter. Finally, Revere Asset Management Inc purchased a new position in VanEck Pharmaceutical ETF during the 3rd quarter valued at about $15,628,000.

VanEck Pharmaceutical ETF Price Performance

Shares of NASDAQ PPH opened at $111.20 on Monday. VanEck Pharmaceutical ETF has a 1 year low of $82.37 and a 1 year high of $114.57. The firm has a 50-day moving average of $107.92 and a 200 day moving average of $106.04. The stock has a market cap of $938.53 million, a P/E ratio of 20.21 and a beta of 0.46.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Wednesday, July 1st were issued a dividend of $0.6248 per share. This represents a $2.50 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.